Telix Pharmaceuticals Ltd (ASX: TLX) shares have been on fire this week.

Despite the market weakness, the radiopharmaceuticals company’s shares have rocketed around 14% higher.

The catalyst for this has been news that the company’s Pixclara product has been granted US FDA approval.

So, should you be buying Telix shares as well because of this big news? Let’s find out what Bell Potter thinks.

What is the broker saying?

Bell Potter was pleased with the Pixclara news, highlighting that Telix is entering a new era with revenues set to jump in FY 2027. It said:

The FDA’s approval of the new drug application for Pixclara (floretyrosine F18 aka FET-PET) heralds a new era for TLX, expanding its revenue base beyond the PSMA imaging. In fact, TLX now has multiple revenue streams inclusive of it is isotope manufacturing business, with FY27 revenues now likely to expand well beyond the US$1bn mark .

Speaking about the product, the broker adds:

The work now commences to execute on the commercialisation strategy commencing with the establishment of reimbursement and the appointment of radiopharmaceutical networks for distribution.

We expect strong demand from the outset as FET-PET is the standard of care for the management of gliomas outside of the US. The drug has been available to a limited extent under the expanded access program in the US and there is a highly concentrated user group amongst radiation oncologists. The premium reimbursement relative to reimbursement on most other nuclear medicine exams will help prioritise FET-PET for machine time.

Should you invest?

According to the note, in response to the news, Bell Potter upgraded Telix shares to a buy rating with a $19.00 price target.

Based on its current share price of $17.75, this implies potential upside of 7% for investors.

Commenting on its investment thesis, it said:

First revenues expected 2Q27. Revenues will be modest in the initial instance and not material to overall revenue growth in the short term. Despite this, the Pixclara approval is an important catalyst, particularly if the label expands to the larger brain metastases indication. We had previously included revenues from Pixclara in forecasts, hence no changes to earnings required. We upgrade our recommendation from Hold to Buy, PT $19.00.

Overal, the broker appears to see potential for Telix shares to keep climbing in the near term. Though, the easy gains appear to be behind them.

The post Are Telix shares a buy after its big US FDA news? appeared first on The Motley Fool Australia.

More reading

• These 2 ASX healthcare shares just jumped up to 15%. Here’s why
• Here are the top 10 ASX 200 shares today
• Buy, hold, sell: Domino’s Pizza, Telix Pharmaceuticals, Westfarmers shares
• Here are the top 10 ASX 200 shares today
• Why are Telix Pharmaceuticals shares charging higher today?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The James Hardie Industries PLC (ASX: JHX) share price is in focus after the company hosted its 2026 Investor Day, where it reaffirmed guidance and raised its free cash flow target for FY27. Management highlighted the rapid progress on cost synergies and provided a strategic growth outlook.

What did James Hardie report?

• Targets annual organic growth of 4% to 7% above market, with compounding earnings
• Expects to deliver US$125 million in cost synergies one year ahead of schedule
• US$500 million in revenue synergies from the AZEK integration remain on track
• Raised FY27 free cash flow target; reaffirmed FY27 net sales and Adjusted EBITDA guidance (excluding Europe)
• Commits to capital allocation priorities, aiming to reduce net leverage to below 2.0x by Q2 FY28

What else do investors need to know?

James Hardie is accelerating the integration with AZEK, achieving faster-than-expected cost synergy targets. The company expects to complete the US$125 million cost synergy target a full year ahead of schedule, while revenue synergies are progressing as planned.

The company is pressing ahead with the divestment of its European operations for about US$980 million. Proceeds are earmarked to pay down debt and fund share buybacks, which should support balance sheet strength and shareholder returns.

What did James Hardie management say?

Chief Executive Officer Aaron Erter said:

We are also introducing our financial growth algorithm that outlines the building blocks to deliver 4% to 7% growth above market. This will be driven by a $23 billion material conversion opportunity, self-help growth initiatives, and $500 million in anticipated revenue synergies – all without underwriting a housing recovery.

What’s next for James Hardie?

James Hardie reaffirmed its FY27 sales and Adjusted EBITDA targets and lifted its free cash flow outlook, signalling confidence despite broader macroeconomic challenges. The company is prioritising organic growth, disciplined capital allocation—including debt reduction—and further bolt-on acquisitions.

Management’s focus on compounding earnings and a robust North American growth strategy puts James Hardie on a path to deliver above-market returns, supported by structural drivers in the repair, remodel and new-build markets.

James Hardie share price snapshot

Over the past 12 months, James Hardie shares have risen 31%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has declined 2% over the same period.

View Original Announcement

The post James Hardie lifts guidance and details long-term growth at 2026 Investor Day appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Echo IQ, James Hardie, Woolworths shares
• Experts reckon this high-flying ASX 200 blue-chip stock is a buy
• This ASX 200 stock is up 30% in 2026. Here’s why I’d still buy it
• Where I’d invest $20,000 in ASX shares this spring
• ASX 200 mining shares outperform in final week of earnings season

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Passive income is one key reason to invest in ASX shares.

Once you have built a large enough portfolio, money can arrive in your account without having to work another hour for it.

That could eventually mean extra holidays, fewer days at work, help with household bills, or simply more freedom.

Yet I think many people underestimate what they could build by starting with relatively modest amounts.

Let’s look at what could happen with $500 a month.

Getting started

Investing $500 does not feel life-changing in itself.

Even after a year, you would have contributed just $6,000.

But the real value of those early investments is the amount of time they have to compound.

If $500 were invested every month and the portfolio generated an average return of 10% per annum, the balance could grow to approximately $100,000 after 10 years.

After 15 years, it could be worth around $200,000.

And after 20 years, the portfolio could reach approximately $360,000.

These figures assume returns are reinvested and are only illustrations. A 10% annual return is possible to achieve, but certainly not guaranteed.

Overall, I think this demonstrates how seemingly small decisions made today can have major consequences decades later.

I wouldn’t chase dividends straight away

If I were starting this portfolio from scratch, income would not be my main priority.

I would want to grow the capital first. That could mean investing in high-quality ASX growth shares such as Xero Ltd (ASX: XRO), Goodman Group (ASX: GMG), and ResMed Inc (ASX: RMD).

Blue chips such as Wesfarmers Ltd (ASX: WES) could also have a role.

And ASX exchange traded funds (ETFs) such as the iShares S&P 500 ETF (ASX: IVV) or Vanguard MSCI Index International Shares ETF (ASX: VGS) could provide exposure to hundreds of global companies.

The aim during these years would be simple. It would be to keep investing, reinvest anything the portfolio pays out, and give compounding as much time as possible.

Turning growth into income

To generate $26,000 of passive income, I would target a portfolio valued at approximately $520,000 and a 5% dividend yield across it.

At our assumed 10% return, investing $500 every month could take the portfolio to this level in roughly 23 years.

Once there, this is when I would start thinking much more seriously about income.

Some of the growth investments could remain, while more money could gradually move toward dividend shares such as APA Group (ASX: APA), Transurban Group (ASX: TCL), HomeCo Daily Needs REIT (ASX: HDN), and Charter Hall Long WALE REIT (ASX: CLW).

A $520,000 portfolio yielding 5% would then produce $26,000 a year.

And all of it could have started with the decision to put aside $500 each month.

The post How to make $26,000 of passive income from ASX shares appeared first on The Motley Fool Australia.

More reading

• 3 excellent ASX dividend shares with 5.5% to 7.7% yields
• How much superannuation do I need to earn $70,000 per year in passive income?
• Here are the top 10 ASX 200 shares today
• Buy, hold, sell: Domino’s Pizza, Telix Pharmaceuticals, Westfarmers shares
• WiseTech Global vs Xero: Which fallen ASX tech share is the better buy today?

Motley Fool contributor James Mickleboro has positions in Goodman Group, ResMed, and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goodman Group, ResMed, Transurban Group, Wesfarmers, Xero, and iShares S&P 500 ETF. The Motley Fool Australia has positions in and has recommended Apa Group, ResMed, Transurban Group, and Xero. The Motley Fool Australia has recommended Goodman Group, HomeCo Daily Needs REIT, Vanguard Msci Index International Shares ETF, Wesfarmers, and iShares S&P 500 ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.